In an unprecedented change, the Centers for Disease Control and Prevention reduced the number of vaccines recommended for all children on Monday. One of them is the hepatitis B vaccine, a three-dose ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual property developed by Monsanto, the crop science company the German company ...

A Moderna spokesperson said the company is aware of the lawsuit and will defend itself. Spokespeople for Pfizer, BioNTech and Johnson & Johnson did not immediately respond to requests for comment.

Longtime Pfizer R&D chief Kathy Fernando, Ph.D., has left the Big Pharma behind to take on the role of chief business officer at San Diego biotech Replicate Bioscience. There, she’ll work to advance ...

A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and Novavax (NVAX) to trade lower on Tuesday, just as a major safety scare related ...

"We are not going back to before Louis Pasteur times,” declared Pfizer CEO Andrew Bourla on a Tuesday morning analyst call, saying the pharma giant will continue its “long-term investment” in vaccines ...

The US Food and Drug Administration intends to put a “black box” warning on Covid-19 vaccines, according to two people familiar with the agency’s plans, the latest move by President Donald Trump’s ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

The director of the Food and Drug Administration’s vaccine division told agency staff in a memo that an internal review found that at least 10 children died “after and because of receiving” the Covid ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Shares of Pfizer, Inc. (NASDAQ: PFE) are trading higher after a study found that the company’s new mRNA flu vaccine outperforms traditional shots against predominant strains. What To Know: A study ...